Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant human anti-rabies virus monoclonal antibody injection in healthy adults
CTR20260293Phase 2Active
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human anti-rabies virus monoclonal antibody in rabies, sponsored by Lanzhou Institute of Biological Products Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
recombinant human anti-rabies virus monoclonal antibody
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20260293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260293.